{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:13:13Z","timestamp":1793779993801,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Accurate differentiation of pseudoprogression (PsP) from tumor progression (TP) in glioblastomas (GBMs) is essential for appropriate clinical management and prognostication of these patients. In the present study, we sought to validate the findings of our previously developed multiparametric MRI model in a new cohort of GBM patients treated with standard therapy in identifying PsP cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Fifty-six GBM patients demonstrating enhancing lesions within 6\u00a0months after completion of concurrent chemo-radiotherapy (CCRT) underwent anatomical imaging, diffusion and perfusion MRI on a 3\u00a0T magnet. Subsequently, patients were classified as TP\u2009+\u2009mixed tumor (n\u2009=\u200937) and PsP (n\u2009=\u200919). When tumor specimens were available from repeat surgery, histopathologic findings were used to identify TP\u2009+\u2009mixed tumor (&gt;\u200925% malignant features; n\u2009=\u200934) or PsP (&lt;\u200925% malignant features; n\u2009=\u200916). In case of non-availability of tumor specimens,\u2009\u2265\u20092 consecutive conventional MRIs using mRANO criteria were used to determine TP\u2009+\u2009mixed tumor (n\u2009=\u20093) or PsP (n\u2009=\u20093). The multiparametric MRI-based prediction model consisted of predictive probabilities (PP) of tumor progression computed from diffusion and perfusion MRI derived parameters from contrast enhancing regions. In the next step, PP values were used to characterize each lesion as PsP or TP+\u2009mixed tumor. The lesions were considered as PsP if the PP value\u00a0was\u2009&lt;\u200950% and TP+\u2009mixed tumor if the PP value\u00a0was\u2009\u2265\u200950%. Pearson test was used to determine the concordance correlation coefficient between PP values and histopathology\/mRANO criteria. The area under ROC curve (AUC) was used as a quantitative measure for assessing the discriminatory accuracy of the prediction model in identifying PsP and TP+\u2009mixed tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Multiparametric MRI model correctly predicted PsP in 95% (18\/19) and TP+\u2009mixed tumor in 57% of cases (21\/37) with an overall concordance rate of 70% (39\/56) with final diagnosis as determined by histopathology\/mRANO criteria. There was a significant concordant correlation coefficient between PP values and histopathology\/mRANO criteria (r\u2009=\u20090.56; p\u2009&lt;\u20090.001). The ROC analyses revealed an accuracy of 75.7% in distinguishing PsP from TP+\u2009mixed tumor. Leave-one-out cross-validation test revealed that 73.2% of cases were correctly classified as PsP and TP\u2009+\u2009mixed tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our multiparametric MRI based prediction model may be helpful in identifying PsP in GBM patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12967-023-03941-x","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:03:34Z","timestamp":1682679814000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Validation of multiparametric MRI based prediction model in identification of pseudoprogression in glioblastomas"],"prefix":"10.1186","volume":"21","author":[{"given":"Laiz Laura","family":"de Godoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suyash","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MacLean P.","family":"Nasrallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald M.","family":"O\u2019Rourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Bagley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie A.","family":"Loevner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harish","family":"Poptani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-7284","authenticated-orcid":false,"given":"Sanjeev","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"issue":"2","key":"3941_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1177\/030089160909500210","volume":"95","author":"OP Erpolat","year":"2009","unstructured":"Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, B\u00fcy\u00fckberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori. 2009;95(2):191\u20137.","journal-title":"Tumori"},{"key":"3941_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68011-4","author":"MTC Poon","year":"2020","unstructured":"Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (\u2265 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020. https:\/\/doi.org\/10.1038\/s41598-020-68011-4.","journal-title":"Sci Rep"},{"key":"3941_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/978-1-4614-3146-6_3","volume":"746","author":"DR Johnson","year":"2012","unstructured":"Johnson DR, Chang SM. Recent medical management of glioblastoma. Adv Exp Med Biol. 2012;746:26\u201340.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"3941_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13063-022-06168-1","volume":"23","author":"M Sun","year":"2022","unstructured":"Sun M, Huang N, Tao Y, Wen R, Zhao G, Zhang X, et al. The efficacy of temozolomide combined with levetiracetam for glioblastoma (GBM) after surgery: a study protocol for a double-blinded and randomized controlled trial. Trials. 2022;23(1):234.","journal-title":"Trials"},{"issue":"3","key":"3941_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/COC.0b013e318210f54a","volume":"35","author":"E Topkan","year":"2012","unstructured":"Topkan E, Topuk S, Oymak E, Parlak C, Pehlivan B. Pseudoprogression in patients with glioblastoma multiforme after concurrent radiotherapy and temozolomide. Am J Clin Oncol. 2012;35(3):284\u20139.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"3941_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.790674","volume":"25","author":"Y Li","year":"2021","unstructured":"Li Y, Ma Y, Wu Z, Xie R, Zeng F, Cai H, et al. Advanced imaging techniques for differentiating pseudoprogression and tumor recurrence after immunotherapy for glioblastoma. Front Immunol. 2021;25(12): 790674.","journal-title":"Front Immunol"},{"issue":"3","key":"3941_CR7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","volume":"134","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017;134(3):495\u2013504.","journal-title":"J Neurooncol"},{"issue":"4","key":"3941_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.surneu.2008.09.023","volume":"72","author":"C Chaskis","year":"2009","unstructured":"Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol. 2009;72(4):423\u20138.","journal-title":"Surg Neurol"},{"key":"3941_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26171","author":"SC Thust","year":"2018","unstructured":"Thust SC, van den Bent MJ, Smits M. Pseudoprogression of brain tumors. J Magn Reson Imaging. 2018. https:\/\/doi.org\/10.1002\/jmri.26171.","journal-title":"J Magn Reson Imaging"},{"key":"3941_CR10","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100008131","author":"GB Rold\u00e1n","year":"2009","unstructured":"Rold\u00e1n GB, Scott JN, McIntyre JB, Dharmawardene M, de Robles PA, Magliocco AM, et al. Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci\/J Canadien des Sciences Neurologiques. 2009. https:\/\/doi.org\/10.1017\/s0317167100008131.","journal-title":"Can J Neurol Sci\/J Canadien des Sciences Neurologiques"},{"issue":"7","key":"3941_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.4719","volume":"35","author":"S Chawla","year":"2022","unstructured":"Chawla S, Bukhari S, Afridi OM, Wang S, Yadav SK, Akbari H, et al. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma. NMR Biomed. 2022;35(7): e4719.","journal-title":"NMR Biomed"},{"key":"3941_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-009-9809-4","volume":"94","author":"ER Gerstner","year":"2009","unstructured":"Gerstner ER, McNamara MB, Norden AD, LaFrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neuro-Oncol. 2009;94:97\u2013101. https:\/\/doi.org\/10.1007\/s11060-009-9809-4.","journal-title":"J Neuro-Oncol"},{"issue":"5","key":"3941_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.3171\/2017.6.JNS17393","volume":"129","author":"DA Goldman","year":"2018","unstructured":"Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS. The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg. 2018;129(5):1231\u20139.","journal-title":"J Neurosurg"},{"issue":"20","key":"3941_CR14","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.7150\/jca.32475","volume":"10","author":"H Zhang","year":"2019","unstructured":"Zhang H, Wang R, Yu Y, Liu J, Luo T, Fan F. Glioblastoma treatment modalities besides surgery. J Cancer. 2019;10(20):4793\u2013806.","journal-title":"J Cancer"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3174\/ajnr.a2397","volume":"32","author":"LCH da Cruz","year":"2011","unstructured":"da Cruz LCH, da Cruz LCH, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. Am J Neuroradiol. 2011;32:1978\u201385. https:\/\/doi.org\/10.3174\/ajnr.a2397.","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"3941_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11060-014-1703-z","volume":"122","author":"T Kazda","year":"2015","unstructured":"Kazda T, Hardie JG, Pafundi DH, Kaufmann TJ, Brinkmann DH, Laack NN. Evaluation of RANO response criteria compared to clinician evaluation in WHO grade III anaplastic astrocytoma: implications for clinical trial reporting and patterns of failure. J Neurooncol. 2015;122(1):197\u2013203.","journal-title":"J Neurooncol"},{"issue":"5","key":"3941_CR17","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3174\/ajnr.A4218","volume":"36","author":"AJ Prager","year":"2015","unstructured":"Prager AJ, Martinez N, Beal K, Omuro A, Zhang Z, Young RJ. Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence. Am J Neuroradiol. 2015;36(5):877\u201385.","journal-title":"Am J Neuroradiol"},{"issue":"1","key":"3941_CR18","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11060-015-1893-z","volume":"125","author":"AA Thomas","year":"2015","unstructured":"Thomas AA, Arevalo-Perez J, Kaley T, Lyo J, Peck KK, Shi W, et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. J Neurooncol. 2015;125(1):183\u201390.","journal-title":"J Neurooncol"},{"issue":"6","key":"3941_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1093\/neuonc\/nov301","volume":"18","author":"V Hatzoglou","year":"2016","unstructured":"Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro Oncol. 2016;18(6):873\u201380.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3941_CR20","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1093\/neuonc\/now148","volume":"19","author":"P Patel","year":"2017","unstructured":"Patel P, Baradaran H, Delgado D, Askin G, Christos P, John Tsiouris A, et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis. Neuro Oncol. 2017;19(1):118\u201327.","journal-title":"Neuro Oncol"},{"issue":"10","key":"3941_CR21","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1007\/s00330-017-4789-9","volume":"27","author":"BRJ van Dijken","year":"2017","unstructured":"van Dijken BRJ, van Laar PJ, Holtman GA, van der Hoorn A. Diagnostic accuracy of magnetic resonance imaging techniques for treatment response evaluation in patients with high-grade glioma, a systematic review and meta-analysis. Eur Radiol. 2017;27(10):4129\u201344.","journal-title":"Eur Radiol"},{"issue":"1","key":"3941_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3174\/ajnr.A4474","volume":"37","author":"S Wang","year":"2016","unstructured":"Wang S, Martinez-Lage M, Sakai Y, Chawla S, Kim SG, Alonso-Basanta M, et al. Differentiating tumor progression from pseudoprogression in patients with glioblastomas using diffusion tensor imaging and dynamic susceptibility contrast MRI. Am J Neuroradiol. 2016;37(1):28\u201336.","journal-title":"Am J Neuroradiol"},{"issue":"4","key":"3941_CR23","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361\u201387.","journal-title":"Stat Med"},{"issue":"2","key":"3941_CR24","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-018-03050-6","volume":"141","author":"SJ Bagley","year":"2019","unstructured":"Bagley SJ, Schwab RD, Nelson E, Viaene AN, Binder ZA, Lustig RA, et al. Histopathologic quantification of viable tumor versus treatment effect in surgically resected recurrent glioblastoma. J Neurooncol. 2019;141(2):421\u20139.","journal-title":"J Neurooncol"},{"issue":"11","key":"3941_CR25","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/cncr.32790","volume":"126","author":"H Akbari","year":"2020","unstructured":"Akbari H, Rathore S, Bakas S, Nasrallah MP, Shukla G, Mamourian E, et al. Histopathology-validated machine learning radiographic biomarker for noninvasive discrimination between true progression and pseudo-progression in glioblastoma. Cancer. 2020;126(11):2625\u201336.","journal-title":"Cancer"},{"issue":"2","key":"3941_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","volume":"14","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Wen PY, Cloughesy TF. Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics. 2017;14(2):307\u201320.","journal-title":"Neurotherapeutics"},{"issue":"3","key":"3941_CR27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.neuroimage.2008.09.027","volume":"44","author":"S Wang","year":"2009","unstructured":"Wang S, Kim S, Chawla S, Wolf RL, Zhang WG, O\u2019Rourke DM, et al. Differentiation between glioblastomas and solitary brain metastases using diffusion tensor imaging. Neuroimage. 2009;44(3):653\u201360.","journal-title":"Neuroimage"},{"issue":"1","key":"3941_CR28","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/jmri.26053","volume":"49","author":"S Chawla","year":"2019","unstructured":"Chawla S, Wang S, Mohan S, Nasrallah M, Verma G, Brem S, et al. Differentiation of brain infection from necrotic glioblastoma using combined analysis of diffusion and perfusion MRI. J Magn Reson Imaging. 2019;49(1):184\u201394.","journal-title":"J Magn Reson Imaging"},{"key":"3941_CR29","doi-asserted-by":"publisher","first-page":"237428951984835","DOI":"10.1177\/2374289519848353","volume":"6","author":"MP Nasrallah","year":"2019","unstructured":"Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, et al. Molecular neuropathology in practice: clinical profiling and integrative analysis of molecular alterations in glioblastoma. Acad Pathol. 2019;6:2374289519848353.","journal-title":"Acad Pathol"},{"issue":"6","key":"3941_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/ijo.2015.214","volume":"40","author":"AE Ivanescu","year":"2016","unstructured":"Ivanescu AE, Li P, George B, Brown AW, Keith SW, Raju D, et al. The importance of prediction model validation and assessment in obesity and nutrition research. Int J Obes. 2016;40(6):887\u201394.","journal-title":"Int J Obes"},{"issue":"1064","key":"3941_CR31","doi-asserted-by":"publisher","first-page":"20160242","DOI":"10.1259\/bjr.20160242","volume":"89","author":"D Molina","year":"2016","unstructured":"Molina D, P\u00e9rez-Beteta J, Luque B, Arregui E, Calvo M, Borr\u00e1s JM, et al. Tumour heterogeneity in glioblastoma assessed by MRI texture analysis: a potential marker of survival. Br J Radiol. 2016;89(1064):20160242.","journal-title":"Br J Radiol"},{"key":"3941_CR32","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2020.02.025","volume":"477","author":"LS Hu","year":"2020","unstructured":"Hu LS, Hawkins-Daarud A, Wang L, Li J, Swanson KR. Imaging of intratumoral heterogeneity in high-grade glioma. Cancer Letters. 2020;477:97\u2013106. https:\/\/doi.org\/10.1016\/j.canlet.2020.02.025.","journal-title":"Cancer Letters"},{"issue":"3","key":"3941_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s11864-011-0157-1","volume":"12","author":"J Fink","year":"2011","unstructured":"Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Curr Treat Options Oncol. 2011;12(3):240\u201352.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"3941_CR34","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/neuonc\/noq197","volume":"13","author":"X Liu","year":"2011","unstructured":"Liu X, Tian W, Kolar B, Yeaney GA, Qiu X, Johnson MD, et al. MR diffusion tensor and perfusion-weighted imaging in preoperative grading of supratentorial nonenhancing gliomas. Neuro Oncol. 2011;13(4):447\u201355.","journal-title":"Neuro Oncol"},{"issue":"1","key":"3941_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0191341","volume":"13","author":"M Neska-Matuszewska","year":"2018","unstructured":"Neska-Matuszewska M, Bladowska J, S\u0105siadek M, Zimny A. Differentiation of glioblastoma multiforme, metastases and primary central nervous system lymphomas using multiparametric perfusion and diffusion MR imaging of a tumor core and a peritumoral zone-Searching for a practical approach. PLoS ONE. 2018;13(1): e0191341.","journal-title":"PLoS ONE"},{"issue":"32","key":"3941_CR36","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3174\/ajnr.a2333","volume":"2011","author":"S Wang","year":"2011","unstructured":"Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, et al. Differentiation between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic susceptibility contrast-enhanced MR imaging. Am J Neuroradiol. 2011;2011(32):507\u201314. https:\/\/doi.org\/10.3174\/ajnr.a2333.","journal-title":"Am J Neuroradiol"},{"issue":"5","key":"3941_CR37","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.acra.2015.11.015","volume":"23","author":"WR Masch","year":"2016","unstructured":"Masch WR, Wang PI, Chenevert TL, Junck L, Tsien C, Heth JA, et al. Comparison of diffusion tensor imaging and magnetic resonance perfusion imaging in differentiating recurrent brain neoplasm from radiation necrosis. Acad Radiol. 2016;23(5):569\u201376.","journal-title":"Acad Radiol"},{"issue":"5","key":"3941_CR38","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.3171\/2018.12.JNS182926","volume":"132","author":"C Li","year":"2019","unstructured":"Li C, Wang S, Yan JL, Torheim T, Boonzaier NR, Sinha R, et al. Characterizing tumor invasiveness of glioblastoma using multiparametric magnetic resonance imaging. J Neurosurg. 2019;132(5):1465\u201372.","journal-title":"J Neurosurg"},{"issue":"1","key":"3941_CR39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.18383\/j.tom.2018.00052","volume":"5","author":"O Stringfield","year":"2019","unstructured":"Stringfield O, Arrington JA, Johnston SK, Rognin NG, Peeri NC, Balagurunathan Y, et al. Multiparameter MRI predictors of long-term survival in glioblastoma multiforme. Tomography. 2019;5(1):135\u201344.","journal-title":"Tomography"},{"key":"3941_CR40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41416-018-0342-0","volume":"120","author":"S Wang","year":"2019","unstructured":"Wang S, O\u2019Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, et al. Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma. Br J Cancer. 2019;120:54\u20136. https:\/\/doi.org\/10.1038\/s41416-018-0342-0.","journal-title":"Br J Cancer"},{"issue":"12","key":"3941_CR41","doi-asserted-by":"publisher","first-page":"337","DOI":"10.25259\/SNI_353_2021","volume":"6","author":"S Mohan","year":"2021","unstructured":"Mohan S, Wang S, Chawla S, Abdullah K, Desai A, Maloney E, et al. Multiparametric MRI assessment of response to convection-enhanced intratumoral delivery of MDNA55, an interleukin-4 receptor targeted immunotherapy, for recurrent glioblastoma. Surg Neurol Int. 2021;6(12):337.","journal-title":"Surg Neurol Int"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-023-03941-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-023-03941-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T11:05:05Z","timestamp":1682679905000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-023-03941-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1186\/s12967-023-03941-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"assertion":[{"value":"19 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from each participant, and the research project was approved by the institutional review board. The study was designed and conducted according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no actual or potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"287"}}